Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 110.49 0.75 (0.68%) Market Cap: 6.97 Bil Enterprise Value: 10.88 Bil PE Ratio: 22.78 PB Ratio: 1.88 GF Score: 78/100

Jazz Pharmaceuticals PLC Xywav Investor Update Transcript

Oct 26, 2020 / 08:30PM GMT
Release Date Price: $148.93 (-0.89%)
Katherine A. Littrell
Jazz Pharmaceuticals plc - VP of IR

Hi. Good day. This is Kathee Littrell, Head of Investor Relations at Jazz. I want to thank you all for joining for our Xywav Investor Update.

Before we begin the webcast, I will point out that we will be making forward-looking statements today including statements regarding our plans and expectations for the Xywav commercial launch in the U.S., potential Xywav's revenue opportunity and our other development plans and opportunities. Our forward-looking statements are subject to risks and uncertainties described in our quarterly report on Form 10-Q for the quarter ended June 30, 2020, and our other filings with the Securities and Exchange Commission and actual results may differ materially. We undertake no duty or obligation to update any forward-looking statements we make today. Finally, we are not confirming or updating any other guidance and actual results may differ.

I'll remind you that you can send in questions at any time during the presentation, and we will address those during the press -- after the presentations are over

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot